Immutep Limited Share

Immutep Limited (IMMP) is a biotechnology company focused on developing novel immunotherapy treatments for cancer and autoimmune diseases. The company's lead product candidate is based on the LAG-3 immune control point, a key regulator of T cell activity. Immutep's research and development efforts are centered on harnessing the power of the immune system to fight disease. Their approach involves activating and enhancing the body's natural defenses to target and eliminate cancer cells and to modulate immune responses in autoimmune disorders. Immutep's pipeline includes a range of clinical and preclinical programs, reflecting a commitment to advancing innovative immunotherapies for patients with significant unmet medical needs. The company operates in the pharmaceutical and biotechnology sector, contributing to advancements in the field of immuno-oncology and autoimmune disease treatment.